Published in J Virol on June 30, 2010
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A (2012) 2.42
In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis (2011) 1.92
Endemic dengue associated with the co-circulation of multiple viral lineages and localized density-dependent transmission. PLoS Pathog (2011) 1.87
The human antibody response to dengue virus infection. Viruses (2011) 1.79
A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog (2011) 1.70
An in-depth analysis of original antigenic sin in dengue virus infection. J Virol (2010) 1.63
Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol (2010) 1.58
Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J Virol (2011) 1.49
Antibody-mediated neutralization of flaviviruses: a reductionist view. Virology (2011) 1.48
Dengue viruses - an overview. Infect Ecol Epidemiol (2013) 1.40
Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog (2012) 1.31
Structural Basis of Zika Virus-Specific Antibody Protection. Cell (2016) 1.27
Genome-wide patterns of intrahuman dengue virus diversity reveal associations with viral phylogenetic clade and interhost diversity. J Virol (2012) 1.25
Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection. J Virol (2013) 1.22
Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay. PLoS Negl Trop Dis (2012) 1.22
Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. PLoS Pathog (2013) 1.20
A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun (2015) 1.18
Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J Virol (2012) 1.17
Innate immunity to dengue virus infection and subversion of antiviral responses. J Mol Biol (2013) 1.17
Structural insights into the neutralization mechanism of a higher primate antibody against dengue virus. EMBO J (2011) 1.17
Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera. J Virol (2012) 1.12
Dengue viruses cluster antigenically but not as discrete serotypes. Science (2015) 1.12
New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol (2015) 1.10
Structural analysis of a dengue cross-reactive antibody complexed with envelope domain III reveals the molecular basis of cross-reactivity. J Immunol (2012) 1.07
Identification of a conserved B-cell epitope on reticuloendotheliosis virus envelope protein by screening a phage-displayed random peptide library. PLoS One (2012) 1.01
Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology (2012) 1.01
Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases. PLoS Negl Trop Dis (2013) 0.98
Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog (2013) 0.97
Structure of acidic pH dengue virus showing the fusogenic glycoprotein trimers. J Virol (2014) 0.95
The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein. PLoS Pathog (2013) 0.94
Development of a humanized antibody with high therapeutic potential against dengue virus type 2. PLoS Negl Trop Dis (2012) 0.93
Genotypic Differences in Dengue Virus Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus Breathing. MBio (2015) 0.92
Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection. MBio (2015) 0.91
Shake, rattle, and roll: Impact of the dynamics of flavivirus particles on their interactions with the host. Virology (2015) 0.91
Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2. PLoS One (2012) 0.90
Structure of the St. Louis encephalitis virus postfusion envelope trimer. J Virol (2012) 0.88
Identification of a conserved JEV serocomplex B-cell epitope by screening a phage-display peptide library with a mAb generated against West Nile virus capsid protein. Virol J (2011) 0.87
Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement. PLoS Pathog (2014) 0.86
An analogue of the antibiotic teicoplanin prevents flavivirus entry in vitro. PLoS One (2012) 0.86
Recombinant Envelope-Proteins with Mutations in the Conserved Fusion Loop Allow Specific Serological Diagnosis of Dengue-Infections. PLoS Negl Trop Dis (2015) 0.86
Dengue serotype cross-reactive, anti-e protein antibodies confound specific immune memory for 1 year after infection. Front Immunol (2014) 0.85
Conservation of the DENV-2 type-specific and DEN complex-reactive antigenic sites among DENV-2 genotypes. Virology (2011) 0.85
Identification of two linear B-cell epitopes from West Nile virus NS1 by screening a phage-displayed random peptide library. BMC Microbiol (2011) 0.85
Analysis of human monoclonal antibodies generated by dengue virus-specific memory B cells. Viral Immunol (2012) 0.84
Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy. Sci Rep (2015) 0.83
Identification of a conserved B-cell epitope on duck hepatitis A type 1 virus VP1 protein. PLoS One (2015) 0.82
Complex phenotypes in mosquitoes and mice associated with neutralization escape of a Dengue virus type 1 monoclonal antibody. Virology (2012) 0.81
Dengue virus infection induces broadly cross-reactive human IgM antibodies that recognize intact virions in humanized BLT-NSG mice. Exp Biol Med (Maywood) (2014) 0.80
Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections. Biomed Res Int (2013) 0.80
Rapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell cultures. MAbs (2015) 0.79
Phage display approaches for the isolation of monoclonal antibodies against dengue virus envelope domain III from human and mouse derived libraries. Int J Mol Sci (2012) 0.79
Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies. Front Microbiol (2015) 0.79
Evolutionarily Successful Asian 1 Dengue Virus 2 Lineages Contain One Substitution in Envelope That Increases Sensitivity to Polyclonal Antibody Neutralization. J Infect Dis (2015) 0.78
The mechanism of differential neutralization of dengue serotype 3 strains by monoclonal antibody 8A1. Virology (2013) 0.78
Functional analysis of dengue virus (DENV) type 2 envelope protein domain 3 type-specific and DENV complex-reactive critical epitope residues. J Gen Virol (2014) 0.77
Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine. J Virol (2014) 0.77
Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus. Vaccine (2017) 0.76
Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys. Clin Vaccine Immunol (2015) 0.76
Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses. PLoS Negl Trop Dis (2016) 0.76
An Epitope-Substituted DNA Vaccine Improves Safety and Immunogenicity against Dengue Virus Type 2. PLoS Negl Trop Dis (2015) 0.76
Highly efficient selection of epitope specific antibody through competitive yeast display library sorting. MAbs (2013) 0.76
Dengue virus antibody database: Systematically linking serotype-specificity with epitope mapping in dengue virus. PLoS Negl Trop Dis (2017) 0.75
A Conserved Epitope Mapped with a Monoclonal Antibody against the VP3 Protein of Goose Parvovirus by Using Peptide Screening and Phage Display Approaches. PLoS One (2016) 0.75
Antigenic analysis of monoclonal antibodies against different epitopes of σB protein of avian reovirus. PLoS One (2013) 0.75
Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity. Microbiol Mol Biol Rev (2016) 0.75
Recombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies. Am J Trop Med Hyg (2016) 0.75
Thermodynamic mechanism for the evasion of antibody neutralization in flaviviruses. J Am Chem Soc (2014) 0.75
A mouse monoclonal antibody against dengue virus type 1 Mochizuki strain targeting envelope protein domain II and displaying strongly neutralizing but not enhancing activity. J Virol (2013) 0.75
Characterization of a Novel Dengue Serotype 4 Virus-Specific Neutralizing Epitope on the Envelope Protein Domain III. PLoS One (2015) 0.75
Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein. PLoS One (2015) 0.75
A tetravalent dengue nanoparticle stimulates antibody production in mice. J Nanobiotechnology (2012) 0.75
Dengue virus specific IgY provides protection following lethal dengue virus challenge and is neutralizing in the absence of inducing antibody dependent enhancement. PLoS Negl Trop Dis (2017) 0.75
Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice. Sci Rep (2017) 0.75
Identification of one B-cell epitope from NS1 protein of duck Tembusu virus with monoclonal antibodies. PLoS One (2017) 0.75
Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development. Front Microbiol (2017) 0.75
Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell (2002) 9.13
Structure of the dengue virus envelope protein after membrane fusion. Nature (2004) 7.97
A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A (2003) 7.76
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
Prospects for a dengue virus vaccine. Nat Rev Microbiol (2007) 4.99
B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol (2003) 4.87
DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med (2003) 4.69
Molecular evolution and distribution of dengue viruses type 1 and 2 in nature. Virology (1990) 4.65
Dengue virus structural differences that correlate with pathogenesis. J Virol (1999) 4.26
Structure of the immature dengue virus at low pH primes proteolytic maturation. Science (2008) 3.86
The origin, emergence and evolutionary genetics of dengue virus. Infect Genet Evol (2003) 3.83
Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology (1998) 3.80
Structures of immature flavivirus particles. EMBO J (2003) 3.62
Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol (2005) 3.58
Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis (1989) 3.53
Microevolution and virulence of dengue viruses. Adv Virus Res (2003) 3.41
Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe (2010) 3.33
Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep (2003) 3.29
Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol (2008) 3.27
The flavivirus precursor membrane-envelope protein complex: structure and maturation. Science (2008) 3.26
Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol (2006) 3.23
New mouse model for dengue virus vaccine testing. J Virol (1999) 3.18
Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog (2010) 3.16
Geographic expansion of dengue: the impact of international travel. Med Clin North Am (2008) 2.91
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol (2007) 2.89
Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol (2004) 2.83
Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J Virol (2002) 2.66
Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol (2004) 2.64
A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology (2005) 2.60
Antigenic structure of the flavivirus envelope protein E at the molecular level, using tick-borne encephalitis virus as a model. J Virol (1989) 2.59
Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J Virol (2001) 2.59
Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology (2007) 2.40
Cell-associated West Nile flavivirus is covered with E+pre-M protein heterodimers which are destroyed and reorganized by proteolytic cleavage during virus release. J Virol (1989) 2.38
Analysis of the steps involved in Dengue virus entry into host cells. Virology (1999) 2.22
Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell (2006) 2.08
Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg (1987) 2.07
The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog (2010) 2.03
Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog (2008) 2.00
Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol (2008) 1.98
Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J Infect Dis (2007) 1.88
Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J (2009) 1.85
Epitopes on the dengue 1 virus envelope protein recognized by neutralizing IgM monoclonal antibodies. Virology (2001) 1.70
Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med (2008) 1.67
Solution structure and antibody binding studies of the envelope protein domain III from the New York strain of West Nile virus. J Biol Chem (2004) 1.66
Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol (2009) 1.65
Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J Gen Virol (2001) 1.63
Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation. Virology (2008) 1.60
Dengue vaccine candidates in development. Curr Top Microbiol Immunol (2010) 1.56
Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog (2010) 1.56
Crystal structure of dengue virus type 1 envelope protein in the postfusion conformation and its implications for membrane fusion. J Virol (2009) 1.52
Association of the pr peptides with dengue virus at acidic pH blocks membrane fusion. J Virol (2009) 1.43
A therapeutic antibody against west nile virus neutralizes infection by blocking fusion within endosomes. PLoS Pathog (2009) 1.41
Essential role of dengue virus envelope protein N glycosylation at asparagine-67 during viral propagation. J Virol (2007) 1.41
The production of antibody by invading B cells is required for the clearance of rabies virus from the central nervous system. PLoS Negl Trop Dis (2009) 1.34
A single nucleotide change in the E protein gene of dengue virus 2 Mexican strain affects neurovirulence in mice. J Gen Virol (1996) 1.30
Flavivirus infection enhancement in macrophages: radioactive and biological studies on the effect of antibody on viral fate. J Gen Virol (1984) 1.29
Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol (2008) 1.26
Mapping to completeness and transplantation of a group-specific, discontinuous, neutralizing epitope in the envelope protein of dengue virus. J Gen Virol (2007) 1.23
Probing the flavivirus membrane fusion mechanism by using monoclonal antibodies. J Virol (2007) 1.21
Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III. Virology (2008) 1.13
On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J Gen Virol (2009) 1.11
Solution structure and structural dynamics of envelope protein domain III of mosquito- and tick-borne flaviviruses. Biochemistry (2004) 1.07
A detailed mutagenesis study of flavivirus cross-reactive epitopes using West Nile virus-like particles. J Gen Virol (2007) 1.07
Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody. J Immunol (2009) 1.05
Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol (2006) 1.04
Genetic and phenotypic characterization of sylvatic dengue virus type 2 strains. Virology (2008) 1.04
Identification of novel small-molecule inhibitors of West Nile virus infection. J Virol (2007) 1.00
Dengue type-2 virus envelope protein made using recombinant baculovirus protects mice against virus challenge. Am J Trop Med Hyg (1994) 0.83
Passive protection assay of monoclonal antibodies against dengue virus in suckling mice. Curr Microbiol (2009) 0.78
Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A (2006) 8.27
Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science (2008) 7.87
Global spread and persistence of dengue. Annu Rev Microbiol (2008) 6.44
Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet (2011) 5.43
Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci U S A (2002) 5.17
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol (2003) 4.87
Emergence and global spread of a dengue serotype 3, subtype III virus. Emerg Infect Dis (2003) 4.29
Herpesvirus latency confers symbiotic protection from bacterial infection. Nature (2007) 4.27
Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet (2011) 4.15
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood (2008) 3.89
The WHO dengue classification and case definitions: time for a reassessment. Lancet (2006) 3.69
Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol (2005) 3.59
Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature (2005) 3.51
2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature (2010) 3.49
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 3.48
Role of CD8+ T cells in control of West Nile virus infection. J Virol (2004) 3.40
Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol (2005) 3.31
Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol (2008) 3.27
The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe (2007) 3.25
Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol (2006) 3.23
Resting CD4+ T cells from human immunodeficiency virus type 1 (HIV-1)-infected individuals carry integrated HIV-1 genomes within actively transcribed host genes. J Virol (2004) 3.17
Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog (2010) 3.16
Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol (2006) 3.15
PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol (2006) 3.13
Differences in dengue severity in infants, children, and adults in a 3-year hospital-based study in Nicaragua. Am J Trop Med Hyg (2005) 3.12
Murine model for dengue virus-induced lethal disease with increased vascular permeability. J Virol (2006) 3.07
A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis (2007) 3.02
A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med (2003) 2.89
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol (2007) 2.89
Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol (2011) 2.85
Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol (2004) 2.83
Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J Infect Dis (2010) 2.80
West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J Virol (2006) 2.79
Recent advances in deciphering viral and host determinants of dengue virus replication and pathogenesis. J Virol (2006) 2.76
Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus. Viral Immunol (2003) 2.69
High seroprevalence of antibodies against dengue virus in a prospective study of schoolchildren in Managua, Nicaragua. Trop Med Int Health (2006) 2.67
Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol (2008) 2.62
Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems. PLoS Pathog (2010) 2.62
IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol (2012) 2.62
Crystal structure of the West Nile virus envelope glycoprotein. J Virol (2006) 2.61
A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology (2005) 2.60
Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J Virol (2006) 2.57
Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and -independent mechanisms. PLoS Pathog (2007) 2.54
Selection for virulent dengue viruses occurs in humans and mosquitoes. J Virol (2005) 2.50
Short report: assessment of the World Health Organization scheme for classification of dengue severity in Nicaragua. Am J Trop Med Hyg (2005) 2.49
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol (2007) 2.45
CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J Virol (2006) 2.44
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A (2012) 2.42
West Nile virus infection and immunity. Nat Rev Microbiol (2013) 2.40
Serotype-specific differences in clinical manifestations of dengue. Am J Trop Med Hyg (2006) 2.39
IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog (2010) 2.39
Multi-country evaluation of the sensitivity and specificity of two commercially-available NS1 ELISA assays for dengue diagnosis. PLoS Negl Trop Dis (2010) 2.33
Human enterovirus 109: a novel interspecies recombinant enterovirus isolated from a case of acute pediatric respiratory illness in Nicaragua. J Virol (2010) 2.31
CD8+ T cells require perforin to clear West Nile virus from infected neurons. J Virol (2006) 2.31
Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol (2007) 2.30
Dynamics of dengue disease severity determined by the interplay between viral genetics and serotype-specific immunity. Sci Transl Med (2011) 2.29
Cutting edge: murine UL16-binding protein-like transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol (2002) 2.26
Evaluation of the traditional and revised WHO classifications of Dengue disease severity. PLoS Negl Trop Dis (2011) 2.26
Infection and injury of neurons by West Nile encephalitis virus. J Virol (2003) 2.25
Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology (2009) 2.24
Diagnosis of dengue virus infection by detection of specific immunoglobulin M (IgM) and IgA antibodies in serum and saliva. Clin Diagn Lab Immunol (2003) 2.22
Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest (2009) 2.18
Efficiency of dengue serotype 2 virus strains to infect and disseminate in Aedes aegypti. Am J Trop Med Hyg (2003) 2.16
Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe (2008) 2.16
The Nicaraguan pediatric dengue cohort study: study design, methods, use of information technology, and extension to other infectious diseases. Am J Epidemiol (2009) 2.14
Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol (2003) 2.13
Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med (2006) 2.11
Evaluation of immunological markers in serum, filter-paper blood spots, and saliva for dengue diagnosis and epidemiological studies. J Clin Virol (2008) 2.10
Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors. Nat Immunol (2003) 2.09
Aedes aegypti vectorial capacity is determined by the infecting genotype of dengue virus. Am J Trop Med Hyg (2006) 2.07
American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J Virol (2003) 2.03
The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog (2010) 2.03